Form D · Biotechnology

Resolys Bio, Inc.

Delanson, NY · CIK 0001674941

Offering snapshot reported Jun 21, 2023 · SEC filing

Reported sold
$50K
Offering amount: $5M
Investors reported
1
Form D · investor count
Minimum accepted
$50K
Reported outside-investor minimum
First sale
Jun 7, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Jun 21, 2023Initial$50,000No comparison1SEC filing
Sep 25, 2017Amendment$200,000No comparison1SEC filing
Dec 5, 2016AmendmentYet to sellNo comparison0SEC filing
May 19, 2016InitialYet to sellNo comparison0SEC filing

Offering details

Securities
Equity
Exemptions
04
Duration over one year
No
Business combination
No
Sales commissions
$4.5K
Finders' fees
$0
Form D file number
021-484769
The broker is paid 9% of each sale made that was initiated by such broker.

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
N/ANoneExemplar Capital, LLC · CRD 155786

Source: Form D, filed Jun 21, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Mc Kay Belk Director
Jeffrey A. Eckmann Director
Chris Garabedian Director, Executive
Thomas Hatch Director
Stephen Hill Director
Damian Marron Director
John Mc Michael Director
Richard Sandberg Executive
James Tobin Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
545 Westfall Road
Delanson, NY, 12053